Latest Updates
Press Releases & News
Press Release
The OPTI-1 trial shows increasing liver-targeted bolus insulin restores liver physiology allowing subjects to decrease Level 2 hypoglycemia by 50% at nighttime
June 2, 2022
Press Release
The OPTI-1 trial shows increasing liver-targeted bolus insulin restores liver physiology allowing subjects to decrease Level 2 hypoglycemia by 50% at nighttime
June 2, 2022
Press Release
The OPTI-1 trial shows increasing liver-targeted bolus insulin restores liver physiology allowing subjects to decrease Level 2 hypoglycemia by 50% at nighttime
June 2, 2022
Press Release
Diasome Pharmaceuticals announces the addition of globally recognized biopharma thought leader and CEO advisor Peter Tollman, PhD as a new Board Member
January 13, 2022
Press Release
Diasome Pharmaceuticals announces the addition of globally recognized biopharma thought leader and CEO advisor Peter Tollman, PhD as a new Board Member
January 13, 2022
Press Release
Diasome Pharmaceuticals announces the addition of globally recognized biopharma thought leader and CEO advisor Peter Tollman, PhD as a new Board Member
January 13, 2022
Press Release
Diasome to Present at the Solebury Trout Summer 2020 Private Company Showcase
August 4, 2020
Press Release
Diasome to Present at the Solebury Trout Summer 2020 Private Company Showcase
August 4, 2020
Press Release
Diasome to Present at the Solebury Trout Summer 2020 Private Company Showcase
August 4, 2020
Press Release
Diasome to Present at the LifeSci Partners Summer Symposium
July 28, 2020
Press Release
Diasome to Present at the LifeSci Partners Summer Symposium
July 28, 2020
Press Release
Diasome to Present at the LifeSci Partners Summer Symposium
July 28, 2020
Press Release
Diasome Announces Substantial Reductions in Level 2 Hypoglycemia Events in its Phase 2b OPTI-1 Study of Hepatocyte Directed Vesicle Technology in Type 1 Diabetes
June 15, 2020
Press Release
Diasome Announces Substantial Reductions in Level 2 Hypoglycemia Events in its Phase 2b OPTI-1 Study of Hepatocyte Directed Vesicle Technology in Type 1 Diabetes
June 15, 2020
Press Release
Diasome Announces Substantial Reductions in Level 2 Hypoglycemia Events in its Phase 2b OPTI-1 Study of Hepatocyte Directed Vesicle Technology in Type 1 Diabetes
June 15, 2020
Press Release
Diasome to Present Data from Phase 2 OPTI-1 Clinical Trial at the 80th Annual American Diabetes Association Virtual Scientific Sessions
June 4, 2020
Press Release
Diasome to Present Data from Phase 2 OPTI-1 Clinical Trial at the 80th Annual American Diabetes Association Virtual Scientific Sessions
June 4, 2020
Press Release
Diasome to Present Data from Phase 2 OPTI-1 Clinical Trial at the 80th Annual American Diabetes Association Virtual Scientific Sessions
June 4, 2020
Press Release
Diasome Announces Positive Results from Phase 2 OPTI-1 Study of Hepatocyte Directed Vesicle Technology in Type 1 Diabetes
February 18, 2020
Press Release
Diasome Announces Positive Results from Phase 2 OPTI-1 Study of Hepatocyte Directed Vesicle Technology in Type 1 Diabetes
February 18, 2020
Press Release
Diasome Announces Positive Results from Phase 2 OPTI-1 Study of Hepatocyte Directed Vesicle Technology in Type 1 Diabetes
February 18, 2020
Press Release
Diasome to Present Additional Data on Hepatocyte Directed Vesicle Technology in Type 1 Diabetes at the Advanced Technologies & Treatment for Diabetes International Conference
February 12, 2020
Press Release
Diasome to Present Additional Data on Hepatocyte Directed Vesicle Technology in Type 1 Diabetes at the Advanced Technologies & Treatment for Diabetes International Conference
February 12, 2020
Press Release
Diasome to Present Additional Data on Hepatocyte Directed Vesicle Technology in Type 1 Diabetes at the Advanced Technologies & Treatment for Diabetes International Conference
February 12, 2020
Press Release
Diasome Appoints Dr. Jeremy Pettus as Chairman of Scientific Advisory Board
December 10, 2019
Press Release
Diasome Appoints Dr. Jeremy Pettus as Chairman of Scientific Advisory Board
December 10, 2019
Press Release
Diasome Appoints Dr. Jeremy Pettus as Chairman of Scientific Advisory Board
December 10, 2019
Journal Article
Divergent Hypoglycemic Effects of Hepatic-Directed Prandial Insulin: A Six-Month Phase 2b Study in Type 1 Diabetes
September 30, 2019
Journal Article
Divergent Hypoglycemic Effects of Hepatic-Directed Prandial Insulin: A Six-Month Phase 2b Study in Type 1 Diabetes
September 30, 2019
Journal Article
Divergent Hypoglycemic Effects of Hepatic-Directed Prandial Insulin: A Six-Month Phase 2b Study in Type 1 Diabetes
September 30, 2019
Journal Article
A new concept for targeting insulin toward the liver could lead to people with diabetes needing less of it to control glycated hemoglobin (A1C) and avoid hypoglycemia.
September 26, 2019
Journal Article
A new concept for targeting insulin toward the liver could lead to people with diabetes needing less of it to control glycated hemoglobin (A1C) and avoid hypoglycemia.
September 26, 2019
Journal Article
A new concept for targeting insulin toward the liver could lead to people with diabetes needing less of it to control glycated hemoglobin (A1C) and avoid hypoglycemia.
September 26, 2019
Press Release
Diasome Announces Publication of Phase 2b Results in Diabetes Care. First ever six-month study of a mealtime liver-targeted insulin.
September 24, 2019
Press Release
Diasome Announces Publication of Phase 2b Results in Diabetes Care. First ever six-month study of a mealtime liver-targeted insulin.
September 24, 2019
Press Release
Diasome Announces Publication of Phase 2b Results in Diabetes Care. First ever six-month study of a mealtime liver-targeted insulin.
September 24, 2019
Press Release
Diasome Announces Completion of Enrollment in Phase 2 OPTI-1 Study of Hepatocyte Directed Vesicle Technology in Type 1 Diabetes
June 25, 2019
Press Release
Diasome Announces Completion of Enrollment in Phase 2 OPTI-1 Study of Hepatocyte Directed Vesicle Technology in Type 1 Diabetes
June 25, 2019
Press Release
Diasome Announces Completion of Enrollment in Phase 2 OPTI-1 Study of Hepatocyte Directed Vesicle Technology in Type 1 Diabetes
June 25, 2019
Interview
Bruce Bode, MD: Hypoglycemic Effect of Hepatic-Directed Insulin
June 17, 2019
Interview
Bruce Bode, MD: Hypoglycemic Effect of Hepatic-Directed Insulin
June 17, 2019
Interview
Bruce Bode, MD: Hypoglycemic Effect of Hepatic-Directed Insulin
June 17, 2019
Press Release
Diasome’s Hepatocyte Directed Vesicle (HDV) Technology Met Primary Endpoint in Phase 2b Trial in Type 1 Diabetes
June 10, 2019
Press Release
Diasome’s Hepatocyte Directed Vesicle (HDV) Technology Met Primary Endpoint in Phase 2b Trial in Type 1 Diabetes
June 10, 2019
Press Release
Diasome’s Hepatocyte Directed Vesicle (HDV) Technology Met Primary Endpoint in Phase 2b Trial in Type 1 Diabetes
June 10, 2019
Press Release
Diasome Announces Presentations at the American Diabetes Association’s 79th Scientific Sessions
May 29, 2019
Press Release
Diasome Announces Presentations at the American Diabetes Association’s 79th Scientific Sessions
May 29, 2019
Press Release
Diasome Announces Presentations at the American Diabetes Association’s 79th Scientific Sessions
May 29, 2019
News Article
Diasome's Father-Son Developing Nanotech to Improve Insulin Effectiveness
April 29, 2019
News Article
Diasome's Father-Son Developing Nanotech to Improve Insulin Effectiveness
April 29, 2019
News Article
Diasome's Father-Son Developing Nanotech to Improve Insulin Effectiveness
April 29, 2019
Interview
Diasome's Liver Targeted Insulin
April 18, 2019
Interview
Diasome's Liver Targeted Insulin
April 18, 2019
Interview
Diasome's Liver Targeted Insulin
April 18, 2019
Press Release
First Patient Enrolled in Phase 2 Study of Hepatocyte Directed Vesicle Technology for People with Type 1 Diabetes
March 28, 2019
Press Release
First Patient Enrolled in Phase 2 Study of Hepatocyte Directed Vesicle Technology for People with Type 1 Diabetes
March 28, 2019
Press Release
First Patient Enrolled in Phase 2 Study of Hepatocyte Directed Vesicle Technology for People with Type 1 Diabetes
March 28, 2019
Interview
Developing Smarter Insulin to Treat Diabetes
February 28, 2019
Interview
Developing Smarter Insulin to Treat Diabetes
February 28, 2019
Interview
Developing Smarter Insulin to Treat Diabetes
February 28, 2019
Press Release
Diasome Pharmaceuticals, Inc. provides 16-month period company update
February 14, 2019
Press Release
Diasome Pharmaceuticals, Inc. provides 16-month period company update
February 14, 2019
Press Release
Diasome Pharmaceuticals, Inc. provides 16-month period company update
February 14, 2019
Press Release
Diasome Pharmaceuticals, Inc. Receives Funding Led By Medicxi
July 5, 2017
Press Release
Diasome Pharmaceuticals, Inc. Receives Funding Led By Medicxi
July 5, 2017
Press Release
Diasome Pharmaceuticals, Inc. Receives Funding Led By Medicxi
July 5, 2017
Press Release
Diasome Pharmaceuticals, Inc. Receives Funding From JDRF T1D Fund
July 5, 2017
Press Release
Diasome Pharmaceuticals, Inc. Receives Funding From JDRF T1D Fund
July 5, 2017
Press Release
Diasome Pharmaceuticals, Inc. Receives Funding From JDRF T1D Fund
July 5, 2017
Interview
2016 Diabetes Symposium in Boston, Robert Geho interviewed by Diabetes in Control publisher Steve Freed
September 17, 2016
Interview
2016 Diabetes Symposium in Boston, Robert Geho interviewed by Diabetes in Control publisher Steve Freed
September 17, 2016
Interview
2016 Diabetes Symposium in Boston, Robert Geho interviewed by Diabetes in Control publisher Steve Freed
September 17, 2016
News Article
After Decades of work, Diasome's insulin additive enters 200-patient trial
August 28, 2016
News Article
After Decades of work, Diasome's insulin additive enters 200-patient trial
August 28, 2016
News Article
After Decades of work, Diasome's insulin additive enters 200-patient trial
August 28, 2016
Press Release
Diasome announces dosing of first type 1 diabetes patient in randomized phase 2b clinical trial of injectable hepatocyte direct vesicle (HDV) technology with insulin
July 29, 2016
Press Release
Diasome announces dosing of first type 1 diabetes patient in randomized phase 2b clinical trial of injectable hepatocyte direct vesicle (HDV) technology with insulin
July 29, 2016
Press Release
Diasome announces dosing of first type 1 diabetes patient in randomized phase 2b clinical trial of injectable hepatocyte direct vesicle (HDV) technology with insulin
July 29, 2016
Press Release
Diasome Pharmaceuticals, Inc. and Lyfebulb, LLC Announce Partnership
March 15, 2016
Press Release
Diasome Pharmaceuticals, Inc. and Lyfebulb, LLC Announce Partnership
March 15, 2016
Press Release
Diasome Pharmaceuticals, Inc. and Lyfebulb, LLC Announce Partnership
March 15, 2016
Press Release
Clinical trial design collaboration with Joslin Diabetes Center
April 27, 2015
Press Release
Clinical trial design collaboration with Joslin Diabetes Center
April 27, 2015
Press Release
Clinical trial design collaboration with Joslin Diabetes Center
April 27, 2015
Press Release
Injected HDV insulin patent allowance
March 31, 2015
Press Release
Injected HDV insulin patent allowance
March 31, 2015
Press Release
Injected HDV insulin patent allowance
March 31, 2015
Press Release
Oral insulin technology patent issues
February 25, 2015
Press Release
Oral insulin technology patent issues
February 25, 2015
Press Release
Oral insulin technology patent issues
February 25, 2015
Journal Article
The importance of the liver in insulin replacement therapy in insulin-deficient diabetes
May 1, 2014
Journal Article
The importance of the liver in insulin replacement therapy in insulin-deficient diabetes
May 1, 2014
Journal Article
The importance of the liver in insulin replacement therapy in insulin-deficient diabetes
May 1, 2014
Press Release
McDonald Partners Engagement
April 9, 2014
Press Release
McDonald Partners Engagement
April 9, 2014
Press Release
McDonald Partners Engagement
April 9, 2014
Study Summary
A single-blind, placebo-controlled, dose-ranging trial of oral hepatic-directed vesicle insulin add-on to oral anti-diabetic treatment in patients with type 2 diabetes mellitus
February 27, 2014
Study Summary
A single-blind, placebo-controlled, dose-ranging trial of oral hepatic-directed vesicle insulin add-on to oral anti-diabetic treatment in patients with type 2 diabetes mellitus
February 27, 2014
Study Summary
A single-blind, placebo-controlled, dose-ranging trial of oral hepatic-directed vesicle insulin add-on to oral anti-diabetic treatment in patients with type 2 diabetes mellitus
February 27, 2014
Journal Article
The preparation and evaluation of tritiated polyalanyl insulin derivates
July 1, 2013
Journal Article
The preparation and evaluation of tritiated polyalanyl insulin derivates
July 1, 2013
Journal Article
The preparation and evaluation of tritiated polyalanyl insulin derivates
July 1, 2013
Press Release
Weight loss patent allowance
March 6, 2013
Press Release
Weight loss patent allowance
March 6, 2013
Press Release
Weight loss patent allowance
March 6, 2013
Journal Article
Hepatic-Directed Vesicle Insulin: a review of formulation development and preclinical evaluation
November 1, 2009
Journal Article
Hepatic-Directed Vesicle Insulin: a review of formulation development and preclinical evaluation
November 1, 2009
Journal Article
Hepatic-Directed Vesicle Insulin: a review of formulation development and preclinical evaluation
November 1, 2009
Study Summary
Clinical trial summary: Single-Blind, Placebo-Controlled, Dose-Ranging trial of Oral HDV-Insulin in Patients with type 2 Diabetes Mellitus
January 9, 2009
Study Summary
Clinical trial summary: Single-Blind, Placebo-Controlled, Dose-Ranging trial of Oral HDV-Insulin in Patients with type 2 Diabetes Mellitus
January 9, 2009
Study Summary
Clinical trial summary: Single-Blind, Placebo-Controlled, Dose-Ranging trial of Oral HDV-Insulin in Patients with type 2 Diabetes Mellitus
January 9, 2009
Study Summary
A Two-Week randomized active comparator study of two HDV-Insulin routes (SC and Oral) and SC Human Insulin in Patients with Type 1 Diabetes Mellitus
June 1, 2008
Study Summary
A Two-Week randomized active comparator study of two HDV-Insulin routes (SC and Oral) and SC Human Insulin in Patients with Type 1 Diabetes Mellitus
June 1, 2008
Study Summary
A Two-Week randomized active comparator study of two HDV-Insulin routes (SC and Oral) and SC Human Insulin in Patients with Type 1 Diabetes Mellitus
June 1, 2008
Study Summary
Hepatic-Directed Vesicles-Insulin: Evaluation of a Novel Oral and Subcutaneous Insulin Delivery System in Animal Models of Diabetes
June 1, 2008
Study Summary
Hepatic-Directed Vesicles-Insulin: Evaluation of a Novel Oral and Subcutaneous Insulin Delivery System in Animal Models of Diabetes
June 1, 2008
Study Summary
Hepatic-Directed Vesicles-Insulin: Evaluation of a Novel Oral and Subcutaneous Insulin Delivery System in Animal Models of Diabetes
June 1, 2008
Journal Article
The effects of HDV-Insulin on carbohydrate metabolism in Type 1 Diabetic patients
March 30, 2001
Journal Article
The effects of HDV-Insulin on carbohydrate metabolism in Type 1 Diabetic patients
March 30, 2001
Journal Article
The effects of HDV-Insulin on carbohydrate metabolism in Type 1 Diabetic patients
March 30, 2001
